GSK plc (NYSE:GSK) Shares Purchased by Simmons Bank

Simmons Bank increased its position in shares of GSK plc (NYSE:GSK) by 3.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 153,319 shares of the pharmaceutical company’s stock after purchasing an additional 4,630 shares during the period. Simmons Bank’s holdings in GSK were worth $6,268,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC increased its holdings in shares of GSK by 448.7% during the 1st quarter. SG Americas Securities LLC now owns 17,690 shares of the pharmaceutical company’s stock worth $758,000 after buying an additional 14,466 shares during the last quarter. Thoroughbred Financial Services LLC purchased a new stake in GSK in the first quarter valued at $277,000. US Bancorp DE raised its position in GSK by 54.6% in the first quarter. US Bancorp DE now owns 181,647 shares of the pharmaceutical company’s stock valued at $7,787,000 after purchasing an additional 64,144 shares during the period. Dearborn Partners LLC lifted its stake in shares of GSK by 21.5% in the 1st quarter. Dearborn Partners LLC now owns 12,992 shares of the pharmaceutical company’s stock valued at $557,000 after purchasing an additional 2,300 shares during the last quarter. Finally, Ledyard National Bank increased its position in shares of GSK by 97.5% during the 1st quarter. Ledyard National Bank now owns 13,366 shares of the pharmaceutical company’s stock worth $573,000 after purchasing an additional 6,597 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Down 2.3 %

Shares of GSK opened at $35.52 on Wednesday. The company’s 50-day simple moving average is $39.65 and its 200-day simple moving average is $40.84. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. GSK plc has a 1 year low of $34.29 and a 1 year high of $45.92. The stock has a market capitalization of $73.62 billion, a PE ratio of 23.07, a P/E/G ratio of 1.39 and a beta of 0.66.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be issued a dividend of $0.3928 per share. The ex-dividend date of this dividend is Friday, November 15th. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a yield of 4.42%. GSK’s dividend payout ratio is 100.00%.

Insider Buying and Selling at GSK

In other news, major shareholder Plc Gsk bought 2,791,930 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the purchase, the insider now owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.00% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Barclays upgraded shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and dropped their target price for the company from $53.00 to $39.50 in a report on Tuesday. Finally, Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Six analysts have rated the stock with a hold rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.